* treatment with immune checkpoint inhibitors, or other immunomodulators within 3 months prior to study enrollment (however, treatment with convalescent plasma, steroids, il-6 inhibitors, and antiviral agents is not excluded) * active bacterial, fungal, or parasitic infection * history of neuromuscular degenerative disease (eg, amyotrophic lateral sclerosis, duchenne muscular dystrophy, or multiple sclerosis) * current participation in an interventional clincial trial * subjects who have, at screening, been on mechanical ventilation for \>7 days have evidence of kidney and liver failure at screening * have a hereditary complement deficiency * pregnancy or breastfeeding

* treatment with immune checkpoint inhibitors, or other immunomodulators within 3 months prior to study enrollment (however, treatment with convalescent plasma, steroids, il-6 inhibitors, and antiviral agents is not excluded) * active bacterial, fungal, or parasitic infection * history of neuromuscular degenerative disease (eg, amyotrophic lateral sclerosis, duchenne muscular dystrophy, or multiple sclerosis) * current participation in an interventional clincial trial * subjects who have, at screening, been on mechanical ventilation for \>7 days have evidence of kidney and liver failure at screening * have a hereditary complement deficiency * pregnancy or breastfeeding

- treatment with immune checkpoint inhibitors, or other immunomodulators within 3 months prior to study enrollment (however, treatment with convalescent plasma, steroids, il-6 inhibitors, and antiviral agents is not excluded) - active bacterial, fungal, or parasitic infection - history of neuromuscular degenerative disease (eg, amyotrophic lateral sclerosis, duchenne muscular dystrophy, or multiple sclerosis) - current participation in an interventional clincial trial - subjects who have, at screening, been on mechanical ventilation for >7 days have evidence of kidney and liver failure at screening - have a hereditary complement deficiency - pregnancy or breastfeeding

- treatment with immune checkpoint inhibitors, or other immunomodulators within 3 months prior to study enrollment (however, treatment with convalescent plasma, steroids, il-6 inhibitors, and antiviral agents is not excluded) - active bacterial, fungal, or parasitic infection - history of neuromuscular degenerative disease (eg, amyotrophic lateral sclerosis, duchenne muscular dystrophy, or multiple sclerosis) - current participation in an interventional clincial trial - subjects who have, at screening, been on mechanical ventilation for >7 days have evidence of kidney and liver failure at screening - have a hereditary complement deficiency - pregnancy or breastfeeding